Invention Grant
- Patent Title: TGF-β inhibitors
-
Application No.: US15860379Application Date: 2018-01-02
-
Publication No.: US10287295B2Publication Date: 2019-05-14
- Inventor: Todd Kinsella , Marina Gelman , Hui Hong , Ihab S. Darwish , Rajinder Singh , Jiaxin Yu , Robert M. Borzilleri , Upender Velaparthi , Peiying Liu , Chetan Padmakar Darne , Hasibur Rahaman , Jayakumar Sankara Warrier
- Applicant: Rigel Pharmaceuticals, Inc. , Bristol-Myers Squibb Company
- Applicant Address: US CA South San Francisco US NJ Princeton
- Assignee: Rigel Pharmaceuticals, Inc.,Bristol-Meyers Squibb Company
- Current Assignee: Rigel Pharmaceuticals, Inc.,Bristol-Meyers Squibb Company
- Current Assignee Address: US CA South San Francisco US NJ Princeton
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Agent Travis Young
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D471/04 ; C07D401/04 ; C07D403/04 ; C07D417/04

Abstract:
Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R′ are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-β, and can be used to treat disease by blocking TGF-β signaling.
Public/Granted literature
- US20180127426A1 TGF-Beta Inhibitors Public/Granted day:2018-05-10
Information query